The possibilities of therapeutic intervention and prevention of cerebrovascular complications in atrial fibrillation in patients on program hemodialysis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is devoted to the important interdisciplinary problem - atrial fibrillation (AF) and the risk of cerebrovascular complications (CVCs) in patients on program hemodialysis (PhD). data on the prevalence of af and its relationship with cvcs are presented, and clinical and pathogenetic variants of af in patients with 5D stage of chronic kidney disease are discussed. The neurological aspects of af in this category of patients and dosage regimens for anticoagulant therapy are considered.

Full Text

Restricted Access

About the authors

Ilkhom T. Murkamilov

I.K. Akhunbaev Kyrgyz State Medical Academy; Kyrgyz-Russian Slavic University n.a. the First President of Russia B.N. Yeltsin

Email: murkamilov.i@mail.ru
PhD in Medical Sciences, Nephrologist, Deputy Associate Professor at the Department of Faculty Therapy Bishkek, Kyrgyzstan

Ibragim S. Sabirov

Kyrgyz-Russian Slavic University n.a. the First President of Russia B.N. Yeltsin

Email: sabirov_is@mail.ru
Doctor of Medical Sciences, Professor, Head of the Department of Therapy № 2 in the specialty “Medical Care Bishkek, Kyrgyzstan

Victor V. Fomin

Sechenov First Moscow State Medical University

Email: fomin_vic@mail.ru
Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences, Vice-Rector for Clinical Work and Postgraduate Professional Education, Director of the V.N. Vinogradov Faculty Therapy Clinic, Head of the Faculty Therapy Department № 1 Moscow, Russia

Kuvanych A. Aitbaev

Scientific Research Institute of Molecular Biology and Medicine at the National Center for Cardiology and Therapy of the Ministry of Health of the Kyrgyz Republic

Email: kaitbaev@yahoo.com
Doctor of Medical Sciences, Professor, Head of the Laboratory of Pathological Physiology Bishkek, Kyrgyzstan

A. Abdulakhatovich Yusupov Furkat

Osh State University

Email: furcat_y@mail.ru
Doctor of Medical Sciences, Professor, Head of the Department of Neurology and Psychiatry, Faculty of Medicine Osh, Kyrgyzstan

Nodira A. Regzhapova

Osh State University

Email: nredzhapova@mail.ru
Postgraduate Student at the Department of Neurology and Psychiatry, Faculty of Medicine Osh, Kyrgyzstan

Akpay Sh. Sarybaev

National Center for Cardiology and Therapy named after Acad. Mirsaid Mirrahimov at the Ministry of Health of the Kyrgyz Republic

Email: ak_sar777@mail.ru
Doctor of Medical Sciences, Professor, Deputy General Director Bishkek, Kyrgyzstan

Bakyt Zh. Imanov

National Center for Cardiology and Therapy named after Acad. Mirsaid Mirrahimov at the Ministry of Health of the Kyrgyz Republic

Email: bimanov@mail.ru
PhD in Medical Sciences, Senior Researcher at the Department of Ultrasound Diagnostics Bishkek, Kyrgyzstan

Gulnara U. Asymbekova

Kyrgyz-Russian Slavic University n.a. the First President of Russia B.N. Yeltsin

Email: ginak@krsu.edu.kg
Doctor of Medical Sciences, Professor, Department of Obstetrics and Gynecology Bishkek, Kyrgyzstan

Abdubakir A. Ibragimov

I.K. Akhunbaev Kyrgyz State Medical Academy

Email: top.sm2014@mail.ru
PhD in Medical Sciences, Therapist, Associate Professor at the Department of Faculty Therapy Bishkek, Kyrgyzstan

Anara B. Mamytova

Kyrgyz-Russian Slavic University n.a. the First President of Russia B.N. Yeltsin

Email: demilge@bk.ru
Doctor of Medical Sciences, Professor, Head of the Department of Surgical Dentistry Bishkek, Kyrgyzstan

Bakyt D. Isakov

Bishkek Research Center for Traumatology and Orthopedics

Email: bakytr@mail.ru
Doctor of Medical Sciences, Deputy Director for Organizational and Methodological Work Bishkek, Kyrgyzstan

Mira I. Isaeva

Medical Center “Nephro Doctor”

Email: mira.isaeva@mail.ru
PhD in Medical Sciences, Nephrologist, Transplantologist, Associate Professor Bishkek, Kyrgyzstan

Farida K. Baysymakova

Republican Diagnostic Center

Email: asatkulovich@mail.ru
Nephrologist Bishkek, Kyrgyzstan

AparkulSh. Sharsheevna Kurumshieva

I.K. Akhunbaev Kyrgyz State Medical Academy

Email: kgma.gospter@mail.ru
PhD in Medical Sciences, Nephrologist, Associate at the the Department Bishkek, Kyrgyzstan

Burma S. Sarymsakova

National Hospital of the Ministry of Health of the Kyrgyz Republic

Email: body_fly@inbox.ru
Nephrologist Bishkek, Kyrgyzstan

Ziyabidin A. Aidarov

I.K. Akhunbaev Kyrgyz State Medical Academy

Email: aydarov.ziabidin.65@mail.ru
Doctor of Medical Sciences, Professor, Head of the Department of Public Health and Healthcare Service Bishkek, Kyrgyzstan

References

  1. Ravani P., Quinn R., Oliver M., et al. Examining the association between hemodialysis access type and mortality: the role of access complications. Clin. J. Am. Soc. Nephrol.2017;12(6):955-64. Doi: https://doi.org/10.2215/ CJN.12181116.
  2. ESRD Patients in 2013. A Global Perspective [Electronic resource]. Fresenius Medical Care. URL: http://www.vision -fmc.com/files/ESRD_Patients_ in_2013.pdf.
  3. USRDS 2013 Annual Data Report: Atlas of chronic kidney disease and end - stage renal disease in the United States [Electronic resource]/ National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2013. URL: http://www.usrds.org/atlas.aspx.
  4. Cozzolino M, Mangano M., Stucchi A., et al. Cardiovascular disease in dialysis patients. Nephrol. Dial. Transplant. 2018;33:(3).iii28-iii34. Doi: https://doi. org/10.1093/ndt/gfy174.
  5. Herrington W, Haynes R., Staplin N., et al. Evidence for the prevention and treatment of stroke in dialysis patients. Seminars in dialysis. 2015;28:1:35-47. Doi: https://doi.org/10.1111/sdi.12281
  6. Chandrashekar A., Ramakrishnan S., Rangarajan D. Survival analysis of patients on maintenance hemodialysis. Indian J. Nephrol. 2014;24(4):206-213. doi: 10.4103/0971-4065.132985.
  7. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 1998-2013 гг. Отчет по данным Российского регистра заместительной почечной терапии. Часть первая. Режим доступа: http://www.nephro.ru/index.php?r=site/contentView&id=12. (дата обращения 26.01.2018)
  8. John T. Dandirdas., Kunig P., Neyer U., et al. Neurological disease of renal failure. Neurol. General Med. 3rd. 2002;131-142.
  9. Статинова Е.А. Неврологические осложнения у больных хронической почечной недостаточностью, находящихся на лечении программным гемодиализом (обзор литературы). Международный неврологический журнал. 2008;2:144-148.
  10. Айтбаев К.А., Муркамилов И.Т., Фомин В.В. и др. Воспаление при хронической болезни почек: источники, последствия и противовоспалительная терапия. Клин. медицина. 2018;4(96):314-320. doi: 10.18821/00232149-2018-96-4-314-320
  11. Ghigolea A.B., Gherman-Caprioara M., Moldovan A.R. Arterial stiffness: hemodialysis versus hemodiafiltration. Clujul. Medical. 2017;90(2):166-170. doi: 10.15386/cjmed-699.
  12. Смирнов А.В. Заместительная почечная терапия. Нефрология. 2011;15:33-46. Doi: https://doi.org/10.24884/1561-6274-2011-15-0-33- 46.
  13. Narula A.S., Jha V, Bali H.K., et al. Cardiac arrhythmias and silent myocardial ischemia during hemodialysis. Ren. Fail. 2000;22(3):355-368.
  14. Суворов А. В., Зубеева Г.Н., Суслова О.А. и др. Нарушение сердечного ритма у больных с терминальной хронической почечной недостаточностью как предиктор сердечно-сосудистого риска. Мед. альманах. 2011;3(16):162-164.
  15. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-сосудистых заболеваний у больных ХПН на хроническом гемодиализе. Нефрология и диализ. 2002;2(4):113-117
  16. Kalra P.A., Green D., Poulikakos D. Arrhythmia in hemodialysis patients and its relation to sudden death.Kidney international. 2018;93(4):781-783. Doi: https://doi.org/10.1016/j.kint.2017.12.005.
  17. Шугушев Х.Х., Хамизова М.М., Василенко В.М., Шугушев З.Х. Показатели вариабельности ритма и аритмии сердца у больных с терминальной стадией хронической почечной недостаточности, находящихся на програмном гемодиализе. Рос. кардиол. журнал. 2003;(4):32-35. Doi: https://doi. org/10.15829/1560-4071-2003-4-32-35.
  18. Михеева Ю.С., Есаян А.М., Румянцев А.Ш. Нарушения ритма при лечении хроническим гемодиализом. Нефрология. 2002;6(2):58-62. Doi: https://doi. org/10.24884/1561-6274-2002-6-2-58-62
  19. Deligiannis A., Kouidi E., Tourkantonis A. Effects of physical training on heart rate variability in patients on hemodialysis. Am. J. Cardiol. 1999;84(2):197-202. Doi: https://doi.org/10.1016/S0002-9149(99)00234-9.
  20. Grande A. Atrial fibrillation and dialysis. A convergence of risk factors. Revista Esp. Cardiol. 2006;59(08):766-769. doi: 10.1016/S1885-5857(07)60041-3.
  21. Samanta R., Chan C., Chauhan V. S. Arrhythmias and Sudden Cardiac Death in End Stage Renal Disease: Epidemiology, Risk Factors and Management. Can. J. Cardiol. 2019. Doi: https://doi.org/10.1016/j.cjca.2019.05.005
  22. Schmitt J., Duray G., Gersh B.J., Hohnloser S.H. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur. Heart J. 2008;30(9):1038-1045. Doi: https://doi. org/10.1093/eurheartj/ehn579.
  23. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in atrial fibrillation: a systematic review. Neurol. 2007;6(69):546-554. Doi: https://doi.org/10.1212/01.wnl.0000267275.68538.8d
  24. Парфенов В.А., Вербицкая С.В. Факторы риска и профилактика инсульта при фибрилляции предсердий. Неврология, нейропсихиатрия, психосоматика. 2014;(3):55-60.Doi: http://dx.doi.org/10.14412/2074-2711-2014-3-55-60.
  25. Шутов А.М., Серов В.А., Гердт А.М. и др. Хроническая болезнь почек предрасполагает к фибрилляции предсердий у больных с хронической сердечной недостаточностью. Нефрология. 2008;12(4):49-53. Doi: https:// doi.org/10.24884/1561-6274-2008-12-4-49-53
  26. Lairikyengbam S.K.S., Anderson M.H., Davies A.G. Present treatment options for atrial fibrillation. Postgraduate Med. J. 2003;79(928):67-73. Doi: http:// dx.doi.org/10.1136/pmj.79.928.67.
  27. Atar I., Kona D., Aзikel S., et al. Frequency of atrialfibrillation andfactors related to its development in dialysis patients. Internat. J. Cardiol. 2006;106(1):47-51.28. Doi: https://doi.org/10.1016/j.ijcard.2004.12.048.
  28. Genovesi S., Pogliani D., Faini A., et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am. J. Kidney Dis. 2005;46(5):897-902. Doi: https://doi.org/10.1053/j. ajkd.2005.07.044
  29. Бокерия Л.А., Шенгелия Л.Д. Механизмы фибрилляции предсердий: от идей и гипотез к эффективному пониманию проблемы. Анналы аритмологии.2014;1(11):4-14. doi: 10.15275/annaritmol.2014.1.1.
  30. Shimizu Y., Maeda K., Imano H., et al. Chronic kidney disease and drinking status in relation to risks of stroke and its subtypes: the Circulatory Risk in Communities Study (CIRCS). Stroke.2011;42(9)2531-2537. Doi: https:// doi.org/10.1161/STROKEAHA.110.600759.
  31. Apostolakis S., Lane D.A., Buller H., Lip G.Y. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb. Haemost. 2013;110(11):1074-1079. doi: 10.1160/TH13-07-0552.
  32. Iguchi Y., Kimura K., Kobayashi K., et al. Relation of atrial fibrillation to glomerular filtration rate. Am. J. Cardiol. 2008;102(8):1056-1059. Doi: https:// doi.org/10.1016/j.amjcard.2008.06.018.
  33. Goette A., Staack T., Rocken C., et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. College Cardiol. 2000;35(6):1669-1677. doi: 10.1016/S0735-1097(00)00611-2.
  34. Chen P.S., Chen L.S., Fishbein M.C., et al. Role of the autonomic nervous system in atrialfibrillation: pathophysiology and therapy. Circulat. Res. 2014;114(9):1500-1515. Doi: https://doi.org/10.1161/CIRCRESAHA.114.303772.
  35. Руководство по нарушениям ритма сердца. Под ред. Е.И. Чазова, С.П. Голицына. М., 2008. 416 с.
  36. Mykytei O. Clinical and instrumental indices and features of risk factors for patients with recurrent ischemic stroke. East Eur. J. Neurol. 2016;6:(12):27-36. Doi: https://doi.org/10.33444/2411-5797.2016.6(12).27-36.
  37. Coumel P. Neural aspects of paroxysmal atrial fibrillation. Atrial fibrillation: mechanisms and management. 1992. Р.109-125.
  38. Мухин Н.А., Глыбочко П.В., Свистунов А.А. и др. Хроническая болезнь почек и фибрилляция предсердий как компоненты кардиоренального континуума. Тер. архив (архив до 2018 г.). 2016;6(88):4-8. Doi: 10.17116/ terarkh20168864-8.
  39. Муркамилов И.Т., Сабиров И.С., Фомин В.В. и др. Оценка нефроцеребрального риска с использованием цистатина Субольных хронической болезнью почек. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(9):10-16. Doi: https://doi.org/10.17116/jnevro201811809110
  40. Дамулин И.В., Андреев Д.А. Фибрилляция предсердий и инсульт. РМЖ. 2015;21(6):41-45
  41. Nayak-Rao S., Shenoy M. P. Stroke in patients with chronic kidney disease..: How do we approach and manage it? Indian J. Nephrol. 2017;27(3):167. doi: 10.4103/0971-4065.202405.
  42. Румянцев А.Ш., Рафрафи Х., Галкина О.В. Кальцификация аортального клапана у больных на программном гемодиализе. Нефрология. 2018;22(4):90-95. Doi: https://doi.org/10.24884/1561-6274-2018-22-4-90- 95.
  43. Bal S., Ojha P., Hill M. D. Stroke prevention treatment of patients with atrial fibrillation: old and new. Curr. Neurol. Neurosci. Rep. 2011;11(1):15-27. Doi: https://doi.org/10.1007/s11910-010-0161-z.
  44. Kessler M., Moureau F., Nguyen P. Anticoagulation in chronic hemodialysis: progress toward an optimal approach. Seminars in Dial. 2015;28(5):474-489. Doi: https://doi.org/10.1111/sdi.12380.
  45. Канорский С.Г., Гиляревский С.Р., Тарасов А.В. и др. Новые рекомендации EHRA по антикоагулянтной терапии у больных с фибрилляцией предсердий: комментарии российских экспертов. Международный журнал сердца и сосудистых заболеваний. 2018;6(19):44-56. doi: 10.15829/23111623-6-19.
  46. Thomson R. How can epidemiological studies help us to prevent stroke? The example of atrial fibrillation. Age and Ageing. 2002;31(Suppl. 3):9-16.
  47. Bohm M., Ezekowitz M.D., Connolly S. J., et al. Changes in renal function in patients with atrialfibrillation: an analysis from the RE-LYtrial. J. Am. College Cardiol. 2015;65(23):2481-2493. doi: 10.1016/j.jacc.2015.03.577.
  48. Harel Z., Chertow G.M., Shah P.S., et al. Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis. Can. J. Cardiol. 2017;33(6):737-746. Doi: https:// doi.org/10.1016/j.cjca.2017.02.004.
  49. Mahmood M., Lip G.Y.H. Nonvitamin K oral anticoagulants in patients with atrial fibrillation and severe renal dysfunction. Revista Esp. Cardiol. (English Edition). 2018;71(10):847-855. Doi: https://doi.org/I0.I0I6/ j.rec.2018.05.015.
  50. Altawalbeh S.M., Alshogran O.Y., Smith K.J. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Value in Health. 2018;21(12):1365-1372. Doi: https://doi.org/10.1016/ jjval.2018.06.009.
  51. Harrington A.R., Armstrong E.P., Nolan Jr P.E., Malone D.C. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676-1681. Doi: https:// doi.org/10.1161/STROKEAHA.111.000402.
  52. Andersen L.V., Vestergaard P., Deichgraeber P., et al. Warfarin for the prevention of systemic embolism in patients with non-valvular atrialfibrillation: a meta-analysis. Heart. 2008;94:12:1607-1613. Doi: http://dx.doi. org/10.1136/hrt.2007.135657.
  53. Мелехов А.В., Дадашова Э.Ф., Никитин И.Г. Нарушение функции почек у пациентов с фибрилляцией предсердий: практические аспекты. Кардиология. 2018;58(1):4-11. Doi: https://doi.org/10.18087/cardio.2427.
  54. Строков А.Г., Гуревич К.Я., Ильин А.П. и др. Лечение пациентов с хронической болезнью почек 5-й стадии (ХБП 5) методами гемодиализа и гемодиафильтрации. клинические рекомендации. Нефрология. 2017;21(3):92-111. Doi: https://doi.org/10.24884/1561-6274-2017-3-92-111
  55. Dahal K., Kunwar S., Rijal J., Schulman P., Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease. Chest. 2016;149(4):951-959. Doi: 10.1378/ chest. 15-1719.
  56. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012;33(21):2719-2747. Doi: https://doi.org/10.1093/eurheartj/ehs253.
  57. Максимов Р.С., Дмитриева Р.В., Деомидов Е.С., Максимова И.Д. Профилактика инсульта при фибрилляции предсердий у пожилых пациентов. Бюллетень медицинских интернет-конференций. 2015;3(5):176-178.
  58. Zhu W., He W., Guo L., et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin. Cardiol. 2015;38(9):555-561. Doi: https://doi. org/10.1002/clc.22435

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies